… in ESR1-mutated metastatic breast cancer (MBC) management, biomarker … biomarker testing recommendations for breast cancer, but they currently … patients with advanced breast cancer with ESR1 mutations, … , such as capecitabine (Xeloda; Genentech, Inc), might …

… without targeted therapy for metastatic breast cancer. Alternatively, they could have … chemotherapy, which consisted of capecitabine (Xeloda; 59.8%), nab-paclitaxel (Abraxane … low or HER2-ultralow metastatic breast cancer following disease progression after …

… (HER2)-mutated metastatic breast cancer (MBC). Mutations in … in combination with capecitabine (Xeloda; Cheplapharm Arzneimittel GmbH) … in HER2-mutated metastatic breast cancer: a phase 2 … patients with advanced HER2+ breast cancer (HER2CLIMB). Updated August …

… [ESR1-mutated advanced breast cancer] that has progressed following … postmenopausal with histologically confirmed breast cancer, positive HR status … 5%), and capecitabine (Xeloda; 11.3% vs 14 … subset of patients with breast cancer. (FALCON). ClinicalTrials.gov …

Metronomic capecitabine (Xeloda; Genetech) plus an aromatase inhibitor … promising option for patients with breast cancer through improved clinical efficacy and … Administration approval overview in metastatic breast cancer. J Clin Oncol. March 19 …

… patients with triple-negative breast cancer (TNBC), circulating tumor … subset having HR–positive breast cancer (12 patients). Among … .8%) and prior therapy Xeloda, (capecitabine) 13.5%). … triple-negative breast cancer or HER2-, BRCA-mutated breast cancer with …

… breast cancer (BC). At the 2024 San Antonio Breast Cancer … ; Novartis) plus capecitabine (Xeloda; Genentech) (9.6 … advanced or metastatic breast cancer (EMILIA). ClinicalTrials.gov … (HER3) positive metastatic breast cancer. ClinicalTrials.gov Identifier: …

… hormone receptor–positive metastatic breast cancer with HER2-low ( … which consisted of capecitabine (Xeloda; 59.8%), nab-paclitaxel … Presented at: San Antonio Breast Cancer Conference; December 10-13 … or HER2-ultralow metastatic breast cancer (mBC) with prior …

… of hormone receptor–positive metastatic breast cancer, most patients see limited benefit … with hormone receptor–positive metastatic breast cancer who had not been … arm, treatment options comprised capecitabine (Xeloda), nab-paclitaxel (Abraxane), and …

… -nxki) for HER2-positive metastatic breast cancer showed “remarkable” outcomes, although it … the regimen of [Tukysa] (tucatinib), [Xeloda] (capecitabine) and Herceptin (trastuzumab). That … With the [Herceptin, Tukysa and Xeloda] regimen, we see more diarrhea …